Almirall S.A. stock (ES0157097017): dermatology-focused pharma after Q1 update and guidance confirmation

Almirall S.A. recently reported first-quarter 2025 results and confirmed its 2025 outlook, highlighting growth in key dermatology brands and continued investment in R&D. The Spain-based specialty pharma group remains focused on medical dermatology, a segment relevant for global and US investors.

Almirall S.A. reported its first-quarter 2025 results on April 29, 2025, posting revenue growth supported by dermatology products and confirming its full-year 2025 guidance, according to the company’s earnings release published that day Almirall investor presentation as of 04/29/2025. The specialty pharmaceutical group highlighted contributions from brands such as Ilumetri in Europe and reported continued investment in late-stage pipeline assets in medical dermatology, as described in its Q1 2025 report Almirall press release as of 04/29/2025.

As of: 05/20/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Almirall
• Sector/industry: Specialty pharmaceuticals, medical dermatology
• Headquarters/country: Barcelona, Spain
• Core markets: Europe and international dermatology markets with selected presence in the United States
• Key revenue drivers: Prescription dermatology medicines, mature primary-care brands, and royalties
• Home exchange/listing venue: BME Spanish Exchanges, Madrid (ticker: ALM)
• Trading currency: EUR

Almirall S.A.: core business model

Almirall focuses on prescription medicines, with a strategic emphasis on medical dermatology such as psoriasis, atopic dermatitis, and acne, according to its corporate profile updated in 2024 Almirall company information as of 2024. The company’s model combines in-house R&D for dermatology innovations with in-licensing and partnerships that expand its portfolio and geographic reach in specialist-driven segments.

In recent years, Almirall has repositioned itself away from a broad primary-care focus toward a more concentrated dermatology franchise, divesting certain non-core assets while strengthening specialist sales capabilities, as outlined in its 2023 annual report published in February 2024 Almirall annual report as of 02/22/2024. This shift aims to capture higher-margin segments and build durable brands supported by long-term prescription use in chronic skin diseases.

The company generates revenue from branded prescription drugs marketed primarily through dermatologists and other specialists, supported by medical education and clinical data. Almirall also earns income from legacy products in respiratory and gastroenterology, as well as from licensing agreements and royalties, which provide cash flow to fund research and business development activities.

Main revenue and product drivers for Almirall S.A.

Growth in Almirall’s topline has been driven by its dermatology portfolio, with biologic and topical treatments for chronic skin conditions taking center stage. Ilumetri (tildrakizumab) for plaque psoriasis has become a key contributor in European markets, where the company continues to expand indications and geographies, according to its 2023 annual report and subsequent Q1 2025 update Almirall annual report as of 02/22/2024. The performance of this biologic platform is central to Almirall’s medium-term growth outlook.

Another contributor in the dermatology franchise is Klisyri (tirbanibulin), used for actinic keratosis, particularly in Europe and the United States. The company has highlighted Klisyri uptake in dermatology practices and is working on expanding market penetration through additional promotional efforts and post-launch studies, as described in its Q1 2025 results release Almirall press release as of 04/29/2025. These products, together with other dermatology brands, form the backbone of Almirall’s strategy to grow in immuno-inflammatory skin diseases.

Beyond currently marketed drugs, Almirall’s pipeline includes mid- to late-stage assets targeting conditions such as atopic dermatitis and other inflammatory skin disorders. The company continues to invest a significant proportion of its revenue into R&D to support clinical trials and regulatory submissions, particularly in Europe and the US, as outlined in its pipeline overview published in 2024 Almirall pipeline information as of 11/15/2024. Successful development and approval of these assets would be important for sustaining longer-term revenue growth.

Homepage and corporate information

Almirall maintains a corporate website that provides information on its strategy, products, pipeline, and sustainability initiatives, aimed at healthcare professionals, patients, and investors. The site offers access to annual reports, quarterly presentations, and press releases, which are key starting points for investors evaluating the company’s financial and strategic progress, as seen on the investor relations section updated regularly in 2024 and 2025 Almirall investor relations as of 04/29/2025.

For US-focused readers, the website also outlines Almirall’s presence in North America, including information on marketed products and clinical study sites. While the company’s primary listing is in Spain, its communications emphasize a global footprint, reflecting the relevance of dermatology markets beyond Europe and the importance of partnerships and trials involving US institutions, as described in its corporate overview as of mid-2024 Almirall company information as of 06/30/2024.

Why Almirall S.A. matters for US investors

Although Almirall is listed in Madrid and reports its financials in euros, its focus on medical dermatology touches disease areas that are highly relevant in the United States, including psoriasis and actinic keratosis. US investors with an interest in global specialty pharma or dermatology innovation may view Almirall as an example of a European-based player with growing international exposure, according to its 2023 annual report and Q1 2025 commentary Almirall annual report as of 02/22/2024.

The company’s collaborations and commercial activities in the US, especially for products like Klisyri, link its performance to trends in the American dermatology market, including reimbursement dynamics and physician adoption. As the US remains the largest pharma market globally, shifts in pricing, competition, or guideline recommendations for dermatology treatments can indirectly influence Almirall’s growth prospects, as discussed in its strategic updates during 2024 and 2025 Almirall investor relations as of 11/07/2024.

For US-based portfolios, Almirall can also serve as a case study in currency exposure, given its euro-denominated reporting, and in the regulatory interplay between the European Medicines Agency and the US Food and Drug Administration for dermatology drugs. Developments such as trial readouts, label extensions, or safety communications in either region may affect the company’s outlook and are closely monitored in its regular newsflow and investor presentations, as seen in its pipeline disclosures in late 2024 Almirall pipeline information as of 11/15/2024.

Conclusion

Almirall S.A. has continued to build its profile as a dermatology-focused specialty pharma company, with Q1 2025 results underscoring the role of key brands and a reaffirmed guidance framework for the year. The business model centers on prescription dermatology assets, supported by targeted R&D and partnerships in Europe and selected international markets. For US investors, the company offers exposure to global dermatology trends and product launches, alongside the usual considerations around currency, regulation, and competition. As always, the risk-reward balance depends on clinical execution, market access, and the broader regulatory and pricing environment in both Europe and the United States.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.